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This prospective study investigated the efficiency of the
tacrolimus (Tac) combined with mycophenolate mofetil
(MMF) alone without immunoadsorption (IA) or
plasmapheresis (PPH) as treatment for early (within 2 weeks)
acute humoral rejection (AHR) in non-sensitized renal
allograft recipients. Of 160 patients enrolled in this
prospective study, 11 patients had histologically and
clinically confirmed early steroid-resistant acute rejection
with an antibody response and received Tac-MMF therapy.
No other aggressive rescue methods such as IA, PPH were
used, according to the study design. Patients (n¼ 11) were
followed for 13.873.5months; nine were females. The
complement-dependent cytotoxicity crossmatch was
negative before transplantation in all patients and only
positive for panel-reactive antibody in one patient. Most of
the rejection episodes were mixed with cellular rejection
(four patients met Banff IIA criteria, five patients met Banff
IIB, one patient met Banff IB, and one patient met Banff
borderline). After 16.1976.16 days of treatment, all rejection
episodes were successfully reversed and all graft functions
were stable, with a mean serum creatinine level of
1.1270.32 mg/dl during follow-up. No patient suffered from
severe infectious complications (except one case of urinary
infection). Our investigation suggests that Tac combined with
MMF alone is adequate to reverse early mixed cellular and
humoral C4d-positive rejection in non-sensitized renal
allograft recipients.
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Alloantibody-mediated acute rejection (AR), also called acute
humoral rejection (AHR), constitutes 20–30% of AR cases in
kidney transplant recipients, and is associated with a poor
prognosis.1,2 It manifests as severe, mostly steroid-resistant,
graft dysfunction, and is associated with a high rate of graft
loss.3–5 In order to reduce the incidence of AHR, the
screening of patients for pre-existing donor-specific anti-
bodies (DSAs) was strengthened. However, DSAs, especially
human lymphocyte antigen-II-reactive antibodies, are not
detectable by conventional methods, whereas very low levels
can be associated with the occurrence of severe AHR post
transplant.6
Combined use of immunoadsorption (IA) or plasmaphere-
sis (PPH), mycophenolate mofetil (MMF) (CellCepts),
tacrolimus (Tac), and/or intravenous immunoglobulins
(IVIG) has been reported to effectively reverse AHR.6–9
Unfortunately, these strategies are costly and are often
complicated by patients developing severe infections.10–12
The treatment is prohibitively expensive for many patients,
particularly those in developing countries. However, some
studies have suggested that IA or PPH may not be necessary
in all AHR patients. Nickeleit et al.13 reported that
antilymphocytic preparation without IA or PPH can
effectively rescue C4d-positive rejection in patients with
pronounced allograft dysfunction; IA or PP has not been
used in their cohort too. Koo et al.14 also observed a good
outcome with anti-thymocyte globulin treatment of early
AHR without IA or PPH.
On the other hand, we found in our previous studies12
that outcome of graft is significantly associated with the onset
time of AHR. AHR occurring during the first 2 weeks had a
statistically better outcome than that occurring more than
2 weeks after transplantation. A further study15 revealed that
AHR onset at different time points is associated with unique
clinico-histopathological manifestations, and suggested that
early and late AHR are each associated with a different
pathogenesis, and may need to be treated separately. Thus, we
began to wonder whether IA or PPH and other aggressive
strategies could be dispensable for patients with early AHR.
Tac combined with MMF (Tac-MMF) has been used
effectively in the treatment of steroid-resistant AR for many
years.16 In a recent study,12 we retrospectively stained C4d in
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grafts with steroid-resistant AR, and were surprised to find
that 480% of Chinese recipients with C4d-positive steroid-
resistant AR could be treated by the simple combination of
Tac-MMF without the need for IA or PPH. We believe most
of these episodes of AR included an antibody-dependent
component, in addition to the cellular rejection. This finding
concurred with the result of a previous study reported by
Pascual et al.,17 in which, although they used PPH
concomitantly, they noticed that Tac-MMF therapy was
critical for successful reversal of AHR.
Based on these findings, it seems that Tac-MMF might be
adequate to treat early AHR after transplantation. This
prospective study aims to further investigate the effectiveness
of a combination of Tac-MMF alone as a treatment of early
(within 2 weeks) AR with an antibody response in Chinese
renal allograft recipients.
RESULTS
Baseline patient characteristics
One hundred and sixty patients were enrolled in this study,
and 20 episodes of AR occurred during the first 2 weeks, all
episodes were proved by biopsy and stained for C4d. Thirteen
were C4d-positive and of these, 11 out of 160 patients (7%)
were diagnosed as having early steroid-resistant AR with an
antibody response (AHR) during the 14-month investigation.
The demographics and the underlying risk factors of the 11
recipients are listed in Table 1. The median age of patients
was 39 years. The proportion of females experiencing early
AHR was significantly greater than the proportion of males
(13.8% (9/65) versus 2.1% (2/95), Po0.01). All of the nine
females had previously been pregnant (range: 1–4 previous
pregnancies). All patients were receiving their first renal
allograft. All transplantations were ABO blood group-
compatible and pre-transplant complement-dependent cyto-
toxicity (CDC) crossmatch were negative. Only one patient
(patient 6) had a positive panel-reactive antibody (PRA)
before transplantation (patients with positive PRA and/or
CDC crossmatch are not usually considered for renal
transplantation in our center). Six recipients received
primary immunosuppression consisting of cyclosporine A
(CsA), MMF, and steroids, and two of these patients also
received two doses of basiliximab as induction therapy. The
other five patients were treated with Tac (initial dose:
1.25 mg/kg day1), MMF, and steroids, and among these
patients two had received two doses of daclizumab as
induction, whereas one had received two doses of
basiliximab as induction. The use of interleukin-2 mono-
clonal antibody as induction therapy had no effect on the
incidence of AHR (7 versus 6% for with versus without inter-
leukin-2 antibody, respectively; P¼ 0.839), even though its
use significantly decreased acute cellular rejection (3 versus
12%; P¼ 0.039).
Clinical manifestations
All of the AHR episodes occurred in the first week (median
4 days post transplant (range: 1–7 days)). The majority of
recipients (n¼ 10) experienced an improvement in initial
graft function (reflected by decrease of serum creatinine
levels) before the AHR occurred (Table 2). Fever, decrease of
urine volume, and progressive allograft dysfunction were
observed as onset manifestation of AHR in all the 11
recipients. Ultrasound examination revealed an enlarged
renal allograft and increased vessel resistance index in each
recipient. Delayed graft function, defined as a need for renal
replacement therapy within the first week of transplant,
occurred in six recipients. No malignant hypertension was
present in this cohort.
Pathology findings
Diagnostic biopsies were performed after the onset of
rejection (median 4 days post onset of rejection (range:
2–11 days)). All patients had neutrophil infiltration in
peritubular capillaries (PTCs), and glomerulitis with neutro-
phils or mononuclear cells infiltration was found in nine
(82%) of 11 diagnostic biopsies (Table 3). Tubulitis was
observed in 36% patients. Three patients had interstitial
hemorrhage. Endo-arteritis was found in all but two cases.
Most episodes of rejection were mixed with cellular rejection.
According to Banff 97 criteria, four patients met the criteria
of IIA, five patients met the criteria of IIB, one patient met
Table 1 | Patients demographics
Case Sex/age Underlying renal disease
Previous
pregnancies
Pre-transplant
perfusion
Previous
transplant
Cold ischemia
time (h)
1 F/54 Interstitial nephritis 4 No No 8.5
2 F/36 CGN 3 No No 16.3
3 F/39 CGN 1 No No 19.5
4 F/39 Polycystic kidney 3 No No 6.7
5 F/42 CGN 1 No No 12.0
6 F/42 CGN 1 No No 9.3
7 F/43 MsPGN 4 No No 10.5
8 M/30 CGN — No No 10.2
9 F/39 CGN 2 No No 13.5
10 M/30 FSGS — No No 8.8
11 F/42 IgAN, FSGS 3 No No 11.3
CGN, chronic glomerularnephritis; F, female; FSGS, focal segmental glomerulosclerosis, IgAN, IgA nephritis; M, male; MsPGN, mesangioproliferative glomerulonephritis.
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IB, and one patient met borderline. C4d staining was positive
in frozen slides in all the 11 patients (Table 3 and Figures 1
and 2). A positive C4d staining was defined as bright linear
staining along capillary basement membranes, involving over
half of sampled capillaries according to 2001 and 2003 Banff
Meetings.18,19 In addition to C4d staining of the PTCs, the
majority of patients also exhibited C3 staining of the
interstitial vasculature which was colocalized with C1q and
IgM in four patients.
Detection of DSAs
In order to determine the level of DSAs after transplantation,
cytotoxic crossmatches and PRA were performed on the day
Table 2 | Clinical characteristics
Onset
of ARa Diagnostic
Dose/trough levels of CNIs
(mg kg1 day1/ng ml1) Diagnosis of rejection
Time of Current Scr
Case (days)
biopsyb
(days) Initial therapy Initial Rescue
Scr
(mg/dl)
Urine output
(ml/day)
effectb
(days)
Reversal of
rejection
(mg/dl,
months)
1 7 2 D+T+M+P 0.10/10.9 0.10/10.0 4.17 250 20 Yes 0.88 (14)
2 2 4 C+M+P 5.5/208 0.13/12.5 CVVH 760 22 Yes 1.00 (13)
3 4 2 C+M+P 5.4/186 0.14/14.5 6.97 640 20 Yes 1.56 (21)
4 1 6 D+T+M+P 0.12/(Not test) 0.12/10.4 6.36 920 20 Yes 0.94 (13)
5 4 6 B+C+M+P 5.1/160 0.15/7.1 CVVH 895 14 Yes 0.91 (13)
6 3 7 B+C+M+P 5.1/102.6 0.12/10.9 CVVH 330 16 Yes 0.96 (11)
7 4 2 C+M+P 5.0/176 0.13/9.1 4.79 1280 12 Yes 1.37 (11)
8 6 2 B+T+M+P 0.12/12.8 0.12/11.2 9.04 1100 12 Yes 1.74 (10)
9 4 4 C+M+P 6.1/348 0.12/12.0 3.26 1050 4 Yes 0.88 (11)
10 2 6 T+M+P 0.11/5.7 0.13/9.2 CVVH 1915 12 Yes 1.24 (16)
11 3 2 T+M+P 0.10/8.3 0.11/9.5 CVVH 150 26 Yes 0.79 (19)
B, basiliximab; CNI, calcineurin inhibitor; CVVH, continuous veno-venous hemofiltration; D, daclizumab; M, mycophenolate mofetil; P, prednisolone; Scr, serum creatinine;
T, tacrolimus.
aDays post-transplantation.
bDays post onset of rejection.
Table 3 | Immunohistochemical and histological evaluation
Inflammatory cell infiltration
Interstitial
Case C4d PTC Glomeruli Interstitial hemorrhage Endarteritis Tubulitis Banff97 grade
1 + +    +  IIA
2 + +++ ++ +  +++  IIB
3 + ++ + +  +++  IIB
4 + + ++   + + IIA
5 + ++ +++  + +++  IIB
6 + +++ +++  + ++ + IIA
7 + + ++   ++  IIA
8 + ++ +++  + +++  IIB
9 + + ++     Borderline
10 + ++  +   + IB
11 + +++ ++ +  +++ + IIB
PTC, peritubular capillary.
+, ++, +++=cortical PTC with 3–4, 5–10, 410 luminal inflammatory cells infiltration, glomeruli with 3–4, 5–10, 410 inflammatory cells infiltration; endarteritis meet the Banff
criteria v1, v2, v3.
Figure 1 | C4d staining in peri-tubular area in renal allograft with
acute humoral rejection. Original magnification 400.
a b
Figure 2 | Typical histological lesions in renal allograft with acute
humoral rejection, (a) neutrophils infiltration in glomeruli,
(b) neutrophils infiltration in peri-tubular area. Original
magnification 400.
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of diagnosis. Eight patients were positive for PRA (sera with
410% flow-PRA class I and/or II reactivity). Donor
lymphocytes were available in seven patients, and CDC
crossmatches were all positive (Table 4). In total, nine
patients had evidence of DSAs and could be diagnosed as
AHR. Two other patients could be diagnosed with suspicious
AHR according to published criteria.20
Rescue treatment and clinical outcome
Following detection of AHR, anti-rejection therapy consist-
ing of steroid bolus (methylprednisolone 500 mg for 3 days)
and a combination of Tac and MMF was used. No patient
had an immediate response to steroid treatment and graft
function deteriorated as manifested by decreased urine
volume and increased serum creatinine; 10 patients received
continuous renal replacement therapy during the treatment
course. After 16.276.2 days of treatment, the urine volume
began to rise and the serum creatinine was gradually
decreased (Figure 3). Ten episodes of AR with an antibody
response (mixed with cellular response) were completely
reversible and one was partially reversible. The function of
all grafts was stable with a mean serum creatinine of
1.1270.32 mg/dl during 13.873.5 months (range: 10–21
months) of follow-up (Table 2).
Complications
Complications with severe infection were not observed
during the follow-up. One female patient developed post
transplant diabetes a month following transplantation, which
was accompanied by a urinary infection caused by Escherichia
coli. The patient recovered after anti-infection therapy with
cefoperazone (4 g/day for 7 days) and converting from Tac to
CsA. The graft function of this patient was stable during the
follow-up.
DISCUSSION
The present study has shown that in Chinese patients
receiving a first renal allograft with a negative CDC
crossmatch and low PRA, a combination of Tac and MMF,
in the absence of IA or PPH, can treat early mixed cellular
and humoral rejection successfully with the prevention of
graft loss. This finding seems contrary to the current
experience with AHR; however, it does support our
prediction and is in accordance with our previous observa-
tions.12
A total of 11 out of 160 (7%) Chinese renal allograft
recipients developed AHR during the first 2 weeks post
transplantation, all of them mixed with cellular rejection
(ranged from Banff borderline to Banff IIB). This incidence
rate is comparable to that observed in non-Asian popula-
tions.2,7,11 However, a significantly larger proportion of
patients with AHR in the present study were female who
had previously been pregnant. This agrees with recent data
showing that pregnancy increases the risk of sensitization to
transplants in women.21,22 Thus, we suggest that the
combination of Tac-MMF should be used as the optimal
initial immunosuppressive protocol in this transplant patient
population.
The established treatment for AHR consists of the
combined use of IA or PPH in addition to MMF, Tac, and/
or IVIG.6–9 Although these therapies are effective, the use of
techniques such as IA and PPH are associated with high costs
and development of severe infections.10–12 However, few
studies have examined the role of Tac-MMF alone in the
Table 4 | Variations of panel reactivity antibody and cytotoxic
crossmatch on diagnosis
Panel reactivity
antibody (HLA-I/II%) CDC crossmatch
Case Pre-transplant
On
diagnosis Pre-transplant
On
diagnosis
1 1.26/4.28 12.0/0.87 Negative Positive
2 0.75/1.23 2.22/18.1 Negative NA
3 5.62/2.33 4.82/3.96 Negative NA
4 0.24/1.98 1.47/0.55 Negative NA
5 0.14/0.08 16.7/15.6 Negative Positive
6 3.65/40 18.8/1.39 Negative NA
7 2.65/0.08 1.78/50.0 Negative Positive
8 0.74/3.66 2.88/0.57 Negative Positive
9 0.10/3.57 2.73/44.1 Negative Positive
10 0.47/1.22 21.2/1.0 Negative Positive
11 2.03/2.14 46.0/22.5 Negative Positive
CDC, complement-dependent cytotoxicity; HLA, human lymphocyte antigen. NA, not
available, donor lymphocytes were not available in these four patients.
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Figure 3 | Recovery of graft function during the course of
treatment. It is reflected through (a) reduction in serum creatinine
and (b) increase in urine output. Data are presented as
mean7standard deviation.
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treatment of AHR. In a recent retrospective study,12 we
reported that the use of Tac-MMF rescue therapy reversed
AHR in Chinese renal allograft recipients, with significantly
reduced infectious complications compared with IA. These
findings are completely consistent with the results from the
current prospective study, and the success rates of both
studies are similar to those obtained with the additional use
of PPH.7,17
AHR is a serious complication for transplant patients and
can lead to graft loss. Therefore, it may seem surprising that
the present study shows that AHR together with cellular
rejection can be resolved using pharmacological measures
alone, without the need for PPH or IA. Actually, it is not
completely unreasonable that Tac-MMF can reverse AHR.
Tac-MMF has been effective in the treatment of steroid-
resistant AR for many years, and reverses about 60%
refractory (even antibody-resistant) rejection cases. We
believe some of them might be antibody-mediated AR. In
1998, Pascual17 reported a cohort of AHR reversed by Tac-
MMF combined with PPH. Although PPH was used in their
protocol, they noticed that Tac-MMF played a critical role in
the reversal of AHR. It is clear that Tac-MMF suppresses the
production of new DSA; that is why most attempts to treat
AHR by removing DSA with PPH were unsuccessful in the
pre-cyclosporine era.23 A previous study had already proved
that MMF can inhibit in vitro antibody production by B
cells.24 This evidence suggests that it is Tac-MMF other than
IA or PPH which is necessary in the treatment of AHR.
Indeed, we are not the first to treat AHR without IA or PPH;
Nickeleit et al.13 and Koo et al.14 reported that antilympho-
cytic preparation without IA or PPH can effectively rescue
C4d-positive rejection with pronounced allograft dysfunc-
tion. As renal allograft recipients from eastern countries
usually need lower doses of immunosuppressants than
Caucasian recipients, the potential differences based on
ethnicity may also contribute to the good outcome of this
cohort. All patients had received bolus steroid; however, it
took 16.1976.16 days for the graft function begun to return.
Maybe steroid had some contributory effect; however, we
believe that the reversal of rejection was mainly due to MMF
and Tac.
Our retrospective studies12,15 also suggested that AHR
developed during the first 2 weeks is usually associated with a
good outcome, and it is late AHR that is associated with
greater graft loss. These may account why we observed such
good outcomes in this cohort. However, our data15 have
proved that this protocol is not as effective in the late AHR
episodes. This study excluded patients with detectable serum
anti-endothelial cell antibodies, which have been associated
with a poor prognosis.25 Kidney transplants were performed
on the basis of a negative pre-transplant CDC crossmatch in
our center, and we also preferred to exclude patients with
high pre-transplant PRA from the waiting list. Thus, patients
may have experienced less intense AHR compared with other
studies. Indeed, the mean peak PRA level of patients in the
current study (21.575.3% (s.e.)) is much lower than that
reported for other transplant populations (B50%).7–9,26 This
investigation also proved that very low levels of anti-donor
antibodies can be associated with the occurrence of severe
AHR post transplant.6,27
It is perhaps counterintuitive that patients who were
already receiving Tac-MMF went on to develop AHR.
However, evidence from the present study suggests that the
DSA might have existed before the initial treatment. Thus,
AHR could have developed in the time required for Tac and
MMF to achieve their effective concentrations. Secondly, the
time taken for the patients’ renal function to recover
(16.276.2 days) correlates with the half-life of serum IgG,
the main component of DSA in patients with AHR.28 Thus, it
appears that the combination of Tac-MMF acts by inhibiting
the de novo production of DSA. These data also suggest that it
might be unwise to excise the graft within 20 days after the
onset of rejection, as graft function may still recover.
Certainly, it would be more reasonable to mitigate the
damage or levels of the antibodies with interventions such as
PPH, IA, or intravenous Ig. Although we do not exclude such
strategies, they are very expensive especially for patients in
developing countries. Our study provides a new alternative
for those who cannot afford such strategies.
We want to emphasize that all episodes of AHR in this
cohort were mixed with cellular manifestations (ranging
from Banff borderline to Banff IIB) and occurred in patients
with an initially negative CDC crossmatch and low levels of
PRA. This accords with a former report29 showing that less
than 5% of cases of C4d-positive AHR met the diagnosis of
so-called ‘pure humoral rejection’. We also noticed that the
incidence of tubulitis and interstitial infiltrations were not
common in this cohort, even in patients with Banff type II
rejection. This may be because most of them had received
one to three dose of bolus steroid treatment before the
biopsy. It appeared that the clinical course of patients in this
group was similar to that of patients with acute tubular
necrosis associated with ischemia–reperfusion injury. How-
ever, acute tubular necrosis is usually associated with
activation of the alternative, but not the classical, pathway
of complement.30 C4d staining was not observed in ischemia
or ischemia–reperfusion injury in perioperative renal trans-
plant biopsies.31 Both the clinical and histological features
observed in this group proved that rejection was antibody-
mediated.
However, ‘pure’ AHR, although rare, may respond in a
different way to anti-rejection therapy than mixed cellular
and humoral C4d-positive rejection. So whether this protocol
is suitable for the treatment of the ‘pure’ AHR remains to be
determined. Similarly, this experience does not apply to
patients intentionally transplanted across a positive cross-
match, and may not apply to crossmatch negative patients
with higher level of pre-transplant PRA.
In conclusion, our study has revealed that the combina-
tion of Tac and MMF, in the absence of PPH or IA, might be
an effective and inexpensive method to treat early mixed
cellular and humoral C4d-positive rejection in renal allograft
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recipients, at least for these non-sensitized patients without
evidence of anti-endothelial cell antibodies. The effect for
sensitized cases and ‘pure’ AHR remains to be determined. As
the incidence of AHR is very low, a large multicenter study
would be helpful to prove these findings.
MATERIALS AND METHODS
Patients
One hundred and sixty cadaveric renal allograft recipients
transplanted between January 2004 and February 2005 in Jinling
Hospital, Nanjing University School of Medicine were enrolled in
this study. A previous study25 had found that AHR with positive
serum anti-endothelial cell antibodies was associated with a poor
graft outcome. Therefore, patients with detectable serum anti-
endothelial cell antibodies were excluded from this study. Informed
consent was obtained from all patients, and the Human Subjects
Committee of Jinling Hospital, Nanjing University School of
Medicine approved all study protocols.
Patients were monitored for AHR episodes according to clinical
manifestations, histological features, C4d staining, and anti-DSAs
detection. Once there were signs of AR, renal allograft biopsy was
performed immediately. We used the followed criteria to include
patients: (1) evidence of severe rejection, resistant to steroid therapy;
(2) C4d deposition in the PTC area, and (3) typical pathologic
features (granulocyte infiltration in glomeruli and PTCs). To verify
the diagnosis criteria, DSA was assessed by post transplant PRAs and
post transplant cytotoxic crossmatch. Steroid-resistant rejection was
defined as serum creatinine levels not returning to within 20% of
baseline within 5 days after the last methylprednisolone pulse.16
Renal allograft pathology and C4d staining
Diagnostic biopsies were performed after the onset of presumed
rejection. Two needle biopsy cores were obtained from each renal
allograft for morphologic study, and divided into two parts: one for
formalin fixation and one for quick-freezing. Hematoxylin and
eosin, periodic acid Schiff, Methenamin-Silver, and Masson staining
were routinely used in the formalin-fixed tissue. Fresh frozen tissue
was analyzed by immunofluorescence microscopy using a conven-
tional panel of antibodies against IgG, IgM, IgA, C3, C4, and C1q.
C4d staining was routinely performed on frozen slides, using an
indirect immunofluorescence technique with a primary affinity-
purified monoclonal antibody (mouse anti-human; dilution, 1:50;
1.5 h incubation at room temperature; Quidel, San Diego, CA, USA)
and an fluorescein isothiocyanate-labeled affinity-purified secondary
rabbit anti-mouse IgG antibody (1:20; 40-min incubation at room
temperature; DAKO, Denmark). Staining was performed according
to standard procedures. All biopsies contained at least 10 glomerular
and two arterial sections. A positive C4d staining was defined as
bright linear staining along capillary basement membranes, invol-
ving over half of sampled capillaries according to 2001 and 2003
Banff Meeting.18,19 Except in two cases (patient 7 and 11), all
patients had received one to three doses of bolus steroid treatment
(500 mg/day) before biopsy.
Initial immunosuppression
Two primary immunosuppressive protocols were used: CsA, MMF
and steroids or Tac, MMF, and steroids. Induction therapy with
either daclizumab or basiliximab could also be used. The choice of
protocol and use of induction therapy was based on the pre-
transplant PRA and crossmatch as well as the patient’s wish. The
initial dose of MMF was 1.5 g/day, as a previous study had shown
that Chinese patients required lower doses of immunosuppressants
than are currently indicated for other populations (2 g/day).32
Calcineurin inhibitors were added when the serum creatinine level
decreased to 50% of pre-transplant (1 h before operation) levels. Tac
was initiated at 0.6 mg/kg day1, CsA was initiated at 4 mg/kg day1,
and both were increased gradually accordingly with the recovery of
graft function. The maintenance doses of Tac and CsA were adjusted
to trough levels: 6–12 ng/ml during the first 6 months and 4–8 ng/ml
during the second 6 months for Tac, and 150–250 ng/ml during the
first 6 months and 100–200 ng/ml during the second 6 months for
CsA. A standard corticosteroid tapering regimen was used,
consisting of an intravenous bolus of methylprednisolone
(500 mg) on days 0–2, followed by oral prednisone 80 mg/day on
day 3, and then tapered 10 mg/day increments to 20 mg/day. The
dose of corticosteroid was then tapered slowly to 5 mg/day
thereafter.
PRA and lymphocytotoxic crossmatch
Before transplantation, human lymphocyte antigen-I and human
lymphocyte antigen-II antigens were routinely detected with flow
cytometry analysis (Flow-PRA) in the method described by Pei et al.
33 Sera with greater than 10% flow-PRA class I and/or II reactivity
were considered anti-human lymphocyte antigen antibody-positive.
Antibody screening was also performed by CDC methods using the
National Institutes of Health technique with undiluted complement
without wash; a dead cells count less than 10% was considered CDC
negative. Kidney transplants were performed on the basis of a
negative pre-transplant CDC crossmatch with donor lymphocytes.
The above-mentioned two methods were also used to determine the
level of DSAs after transplantation. Donor spleen lymphocytes were
stored for future detection of post transplant donor-specific
crossmatch.
Treatment of AHR
During the first 2 weeks, once a rejection episode had occurred,
bolus corticosteroid therapy (methylprednisolone 500 mg optical
density for 3 days) was selected as first-line treatment. Concomi-
tantly, all the patients were given MMF (1.5 g/day) and Tac (trough
levels maintained at 8–15 ng/ml). For patients being treated with
Tac, MMF, and steroids as primary immunosuppression, the dose of
Tac was increased so that trough levels were maintained at 8–15 ng/
ml. If patients needed dialysis, continuous veno-venous hemofiltra-
tion was performed. No other rescue methods such as anti-
thymocyte globulin, IA, or PPH were used. We use complete
reversal, partial reversal, controlled, and lost graft to demonstrate
the outcome of graft, just as we used in a previous study.15 Complete
reversal meant that graft function recovered to the normal range
(1.2 mg/dl in our department) within 1 month of rescue therapy;
partial reversal meant that graft function improved but did not
recover to the normal range within 1 month; controlled meant that
graft function did not improve but remained stable without
dependence on dialysis in the first month; graft loss meant that
the recipient returned to dialysis owing to rejection within 1 month
after the rejection.
Statistics
Results are expressed as the mean7s.d. The analysis was performed
using Stata 6.0 (Stata Corporation, College Station, TX, USA). A w2
test was used for testing the significance of categorical variables, and
Po0.05 was taken as being significant.
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